Hepatocellular carcinoma continues to pose a diagnostic challenge, particularly in the setting of underlying pathomorphological changes in the liver due to cirrhosis, steatosis, or steatohepatitis.

[32–34] In our study, particular interest was applied to those probe sets for which all three terms (HCV ... signatures that distinguish liver cirrhosis associated with two different etiologies ...

Background: It is currently recommended that all patients with liver cirrhosis undergo upper gastrointestinal ... We tried to identify clinical, laboratory and imaging parameters that may predict ...

Cirrhosis is a condition in which scar tissue gradually replaces your healthy liver cells. It usually happens over a long period, often due to hepatitis, alcohol use disorder, or metabolic ...

This inflammation can lead to changes in the liver if it persists. Changes like fibrosis, or scarring of the tissue in the liver, may lead to cirrhosis ... (CT) scan, magnetic resonance imaging ...

Correspondence to Dr Pere Ginès, Liver ... If cirrhosis is mediated by a treatable cause (eg, chronic viral hepatitis, ongoing alcohol consumption, obesity, etc), then patients may have transition ...

The diagnosis was made by CT evidence of subarachnoid blood or positive lumbar puncture in instances where CT imaging was ... during this phase of the evaluation are carefully studied on the next step ...

Correspondence to Miou S Koopman, Radiology and Nuclear Medicine, Amsterdam UMC, location AMC, Amsterdam 1105 AZ, The Netherlands; m.s.koopman{at}amc.uva.nl Background and purpose CT perfusion (CTP ..

Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Department of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang 421002, China ...

Canaccord rates Opthea a buy with target of $1.25 – $3 if Phase III trial is successful Opthea’s lead drug shows strong promise in eye disease trials Positive phase III results could lead to big gains ...

Akero Therapeutics has revealed preliminary topline week 96 outcomes from its Phase IIb SYMMETRY study of efruxifermin (EFX) in individuals with biopsy-confirmed compensated cirrhosis (F4), Child ...